
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Christopher Topoleski, Director of Federal Legislative Affairs for ASHP, talks about the ongoing legislative actions aimed at addressing rising medication costs in the drug industry.
Christopher Topoleski, Director of Federal Legislative Affairs for ASHP, talks about the ongoing legislative actions aimed at addressing rising medication costs in the drug industry.






